# 3B Blackbio DX share price today (3B Blackbio DX Ltd, NSE: 3BBLACKBIO) > 3B Blackbio DX share price today: ₹1,305.10 at the NSE close on 20 November 2026, up 1.8% in a year. 3B Blackbio DX (NSE: 3BBLACKBIO) is worth ₹1,119 crore, trades at a P/E of 19.1 and has closed between ₹1,121.05 and ₹1,695.75 over the past 52 weeks. > 3B Blackbio DX Ltd's earnings have grown faster than its share price. Earnings per share grew +22.9% in a year while the price moved +1.8%. 3BBLACKBIO · Diagnostics · data as of 20 November 2026. Page: https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Growing steadily, from fewer quarters than usual - Price: ₹1,305.10 (+1.8% in a year) - P/E: 19.1× (higher than 56% of the last 11 years) - Revenue (Sep 2026): ₹48.0 Cr (+41.2% on a year ago) - Profit (Sep 2026): ₹18.0 Cr (+20.0% on a year ago) - Operating margin: 43.8% (−0.3 points on a year ago) - ROCE: 25%, FY26 - Profit that came in as cash: 87%, last 3 years Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business. ## What is the 3B Blackbio DX share price today? 3B Blackbio DX Ltd's share price was ₹1,305.10 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 3.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,121 and ₹1,696, and at that close it sat 32% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +13,933% while the NIFTY 500 moved +279%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at 3B Blackbio DX this quarter? Two changes stood out: indian funds and insurers (DIIs) raised their stake for 6 quarters in a row and revenue up on a year earlier for 6 quarters in a row. 1. Indian funds and insurers (DIIs) raised their stake for 6 quarters in a row From 1.6% to 2.3% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 6 quarters in a row In the September 2026 quarter revenue was ₹48 crore, +41.2% on a year earlier. ## What are 3B Blackbio DX's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), 3B Blackbio DX reported revenue of ₹48.0 crore, up 41.2% from ₹34.0 crore a year earlier, and a profit of ₹18.0 crore, up 20.0% from ₹15.0 crore. ### 3B Blackbio DX results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹48.0 crore | ₹34.0 crore | +41.2% | | Profit | ₹18.0 crore | ₹15.0 crore | +20.0% | | Earnings per share | ₹20.74 | ₹17.14 | +21.0% | | Operating margin | 43.8% | 44.1% | −0.3 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 1 June 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the 3B Blackbio DX share price history? 3B Blackbio DX closed at ₹1,305.10 on 20 November 2026, up 1.8% from ₹1,281.40 a year earlier (21 November 2025) and up 211.6% over five years. Its highest weekly close since March 2016 was ₹2,097.45 on 13 December 2024. ### 3B Blackbio DX share price: then and now | When | Close | Change to 20 Nov 2026 | | --- | --- | --- | | 1 week ago · 13 Nov 2026 | ₹1,341.50 | −2.7% | | 1 month ago · 19 Oct 2026 | ₹1,331.20 | −2.0% | | 6 months ago · 22 May 2026 | ₹1,199.20 | +8.8% | | 1 year ago · 21 Nov 2025 | ₹1,281.40 | +1.8% | | 3 years ago · 17 Nov 2023 | ₹723.50 | +80.4% | | 5 years ago · 18 Nov 2021 | ₹418.80 | +211.6% | | 10 years ago · 18 Nov 2016 | ₹18.90 | +6,805.3% | | Earliest weekly close in our records · 11 Mar 2016 | ₹9.30 | +13,933.3% | | Highest weekly close since March 2016 · 13 Dec 2024 | ₹2,097.45 | −37.8% | | Lowest weekly close since March 2016 · 1 Apr 2016 | ₹8.25 | +15,719.4% | | 52-week high (weekly close) · 16 Jan 2026 | ₹1,695.75 | −23.0% | | 52-week low (weekly close) · 5 Jun 2026 | ₹1,121.05 | +16.4% | Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (567 weekly closes from 11 March 2016 to 20 November 2026.) ## What is the latest news on 3B Blackbio DX? 20 Nov 2026: 3B Blackbio DX closed at ₹1,305.10, down 2.7% on the week and down 2.0% on the month. Results for July to September 2026: Revenue up 41.2% and profit up 20.0% on a year earlier. ### Earlier - 22 Sep 2026: ex-date for a dividend of ₹5 a share. - 1 Jun 2026: 3B Blackbio DX held its results call for January to March 2026. ## What dividend does 3B Blackbio DX pay? 3B Blackbio DX paid ₹5 a share in regular dividends in the 12 months to 20 November 2026 (1 payment), a yield of 0.38% at the ₹1,305.10 close on 20 November 2026. The last was a dividend of ₹5 a share, ex-date 22 September 2026. ### 3B Blackbio DX dividends since 1 April 2021 | Ex-date | Dividend per share | Type | | --- | --- | --- | | 22 Sep 2026 | ₹5 | Dividend | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. 3B Blackbio DX Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. (From the NSE corporate-actions record, read 20 November 2026.) ## What to watch in 3B Blackbio DX's next results? When 3B Blackbio DX reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +41.2% on a year earlier, and the last four quarters averaged +62.6%. - Whether the operating margin stays near 43.8%. It is 0.3 percentage points lower than four quarters earlier. - Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +20.0% on a year earlier. ## Which stock lists is 3B Blackbio DX on? 3B Blackbio DX is on one of our India lists: Healthcare & hospital stocks. [Healthcare & hospital stocks Group on the list: Diagnostic labs](https://www.sectoralpha.in/sectors/healthcare-stocks-india) ## Is 3B Blackbio DX profitable? 3B Blackbio DX Ltd earned ₹18.0 Cr of net profit in the Sep 2026 quarter, +20.0% on the same quarter a year earlier. Full-year FY26 profit was ₹60.0 Cr. The Sep 2026 quarter's profit is 37.5% of that quarter's revenue. The same quarter a year earlier earned ₹15.0 Cr. For the full year, FY26 profit was ₹60.0 Cr (+25.0% on the year before). Why profit moved: revenue changed +41.2% on a year earlier and the margin moved −0.3 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +20.9% and revenue +62.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does 3B Blackbio DX make, and is it growing? 3B Blackbio DX Ltd reported ₹48.0 Cr of revenue in the Sep 2026 quarter, +41.2% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 23.6% a year on average. The last full year, FY26, came in at ₹142 Cr. The last four reported quarters add to ₹166 Cr. FY26 revenue was ₹142 Cr, +47.9% on the year before. Recent pace: the last four quarters grew +62.6% on average, against 23.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +61.2%, against +36.6% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +20.4%, against +15.8% a year (accelerating). ## How much of every ₹100 of sales does 3B Blackbio DX keep? 3B Blackbio DX Ltd's operating margin was 43.8% in the Sep 2026 quarter, 0.3 percentage points lower than the same quarter a year ago. Across 13 years it has been between 4.5% and 66.1%. The latest quarter is within that range. Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed +4.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is 3B Blackbio DX's profit turning into cash? Over the last 3 years, 87% of 3B Blackbio DX Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹52.0 Cr of operating cash against ₹60.0 Cr of profit. After ₹26.0 Cr of spending on assets, ₹26.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 87% of profit came in as cash: the cash cycle got 189 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 4.0× depreciation over three years. The next section checks what that spending is building. ## Where does 3B Blackbio DX's cash go? 3B Blackbio DX Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 245 days in FY26, up from 56 days in FY21. It spent ₹28.0 Cr on assets over the last 3 years. Customers take 129 days to pay, and stock sits for 187 days on average. At FY26 sales of ₹142 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹95.0 Cr is tied up in the business at any time. FY26: customers took 129 days to pay and stock sat for 187 days, about 6.2 months of sales sitting as stock, for a full cycle of 245 days, longer than FY21's 56. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 187 days. Customers pay about 129 days after that. Suppliers are paid at 70 days. Together that makes the 245-day cycle. Spending on assets: ₹28.0 Cr over the last 3 years, against ₹7.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is 3B Blackbio DX's P/E ratio, and how does it compare with its own history? 3B Blackbio DX Ltd's P/E is 19.1×, in the middle of its own history: higher than 56% of past readings. Its usual P/E (the middle reading) is 17.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +22.9% while the price moved +1.8%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +25.5% a year; about +4.2% a year came from earnings growth and about +21.3 percentage points from the multiple (the market paying more); over 10 years the price moved +52.7% a year; about +48.0% a year came from earnings growth and about +4.7 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the 3B Blackbio DX business getting better or worse? 3B Blackbio DX Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 25.0% (four quarters to FY26). This is based on 9 quarters of 4 measures, with some gaps. Why it matters: steady growth with healthy returns is how a business compounds over time. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does 3B Blackbio DX earn on its capital? 3B Blackbio DX Ltd earned a ROCE of 25% in FY26. That is up from a low of 7% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 42.3% net margin and 0.38× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 42.3% net margin × 0.38× asset turnover × 1.16× leverage (assets divided by equity) ≈ 18.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does 3B Blackbio DX have too much debt? 3B Blackbio DX Ltd had ₹3.0 Cr of borrowings against ₹325 Cr of equity in FY26, so its debt is 0.01× its equity. Over 5 years borrowings went from ₹2.0 Cr to ₹3.0 Cr. Over the last 3 of those years it spent ₹28.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 41% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the 3B Blackbio DX shareholding pattern? No group of 3B Blackbio DX Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.4 points over the same period, to 2.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −0.8 points over 8 quarters, to 2.5%; Domestic institutions: +0.4 points over 8 quarters, to 2.3%; Promoters: −0.3 points over 8 quarters, to 41.0%. ## How far is 3B Blackbio DX from balance-sheet trouble? For 3B Blackbio DX Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does 3B Blackbio DX rank in its industry? 55.8 out of 100, rank 5 of 9 in Diagnostics, with 82% of the evidence available. 3B Blackbio DX Ltd scores 55.8 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.2 + 17.9 + 8.9 + 7.8 = 55.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is 3B Blackbio DX compared with? 3B Blackbio DX ranks 5 of 9 Diagnostics companies on the 4-Factor Sector Score, with 55.8 out of 100. 1. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) SURAKSHA · leader · Most evidence points up · 93% evidence 71.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 24.9% · Profit 32.3% · Operating margin change 4 points · 100% evidence Capital efficiency 11.4/25 · ROCE 17.3% (year to Mar 2026) · Operating margin 35.4% · 100% evidence Valuation 12.9/20 · P/E 38.8× · PEG 1.4 · 65% evidence Relative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.6% · Strength vs NIFTY 500 (same reading) 14.5% · 1 year 4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 11.4 + 12.9 + 18.6 = 71.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) METROPOLIS · turning · Most evidence points up · 100% evidence 67.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.6/35 · Revenue 19.9% · Profit 42.4% · Operating margin change 2 points · 100% evidence Capital efficiency 13.8/25 · ROCE 17.8% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 11.0/20 · P/E 52.3× · PEG 2.03 · 100% evidence Relative strength 13.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.1% · Strength vs NIFTY 500 (same reading) 5.7% · 1 year 15.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.6 + 13.8 + 11 + 13.9 = 67.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) LALPATHLAB · losing its lead · Evidence leans up · 100% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.5/35 · Revenue 16.7% · Profit 8.7% · Operating margin change 1 points · 100% evidence Capital efficiency 19.3/25 · ROCE 28% (year to Mar 2026) · Operating margin 32% · 100% evidence Valuation 5.3/20 · P/E 57.5× · PEG 2.81 · 100% evidence Relative strength 18.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 16.1% · Strength vs NIFTY 500 (same reading) 18.6% · 1 year 27.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 15.5 + 19.3 + 5.3 + 18.1 = 58.2 · What this means: Relative strength against the index is 18.6%, and revenue and profit growth are weak. 4. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) VIJAYA · losing its lead · Evidence leans up · 100% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 24.3% · Profit 33.5% · Operating margin change 3 points · 100% evidence Capital efficiency 17.5/25 · ROCE 20.5% (year to Mar 2026) · Operating margin 44.3% · 100% evidence Valuation 0.7/20 · P/E 79.5× · PEG 2.88 · 100% evidence Relative strength 12.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 10.5% · Strength vs NIFTY 500 (same reading) 12.5% · 1 year 56.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 27.1 + 17.5 + 0.7 + 12.1 = 57.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. 3B Blackbio DX Ltd this page 3BBLACKBIO · breaking out · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.2/35 · Revenue 61.2% · Profit 20.4% · Operating margin change 1 points · 95% evidence Capital efficiency 17.9/25 · ROCE 25.5% (year to Mar 2026) · Operating margin 43.8% · 76% evidence Valuation 8.9/20 · P/E 19.1× · PEG n/a · 50% evidence Relative strength 7.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -6.3% · Strength vs NIFTY 500 (same reading) -3.4% · 1 year 1.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.2 + 17.9 + 8.9 + 7.8 = 55.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) THYROCARE · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidence Capital efficiency 20.6/25 · ROCE 35.4% (year to Mar 2026) · Operating margin 32.8% · 100% evidence Valuation 7.6/20 · P/E 58.3× · PEG 2.42 · 100% evidence Relative strength 5.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -1.1% · Strength vs NIFTY 500 (same reading) 1% · 1 year 3.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.1 + 20.6 + 7.6 + 5.9 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ONEGLOBAL · quiet · Evidence leans up · 75% evidence 51.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.9/35 · Revenue 42.6% · Profit 41.6% · Operating margin change -2.6 points · 100% evidence Capital efficiency 13.9/25 · ROCE 87% (year to Mar 2026) · Operating margin 16.7% · 100% evidence Valuation 13.9/20 · P/E 11.7× · PEG n/a · 50% evidence Relative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -31.6% · 1 year -30.3% · 25% evidence · 0 of 7 weeks ahead Exact sum: 15.9 + 13.9 + 13.9 + 7.5 = 51.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) KRSNAA · quiet · Evidence leans down · 75% evidence 40.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.4/35 · Revenue 15.9% · Profit 16.5% · Operating margin change -3 points · 100% evidence Capital efficiency 8.4/25 · ROCE 12.7% (year to Mar 2026) · Operating margin 26.2% · 100% evidence Valuation 14.6/20 · P/E 17.2× · PEG n/a · 50% evidence Relative strength 7.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -15.3% · 1 year -36.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 9.4 + 8.4 + 14.6 + 7.9 = 40.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) VIMTALABS · quiet · Evidence leans down · 90% evidence 35.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidence Capital efficiency 15.4/25 · ROCE 25.2% (year to Mar 2026) · Operating margin 33.9% · 100% evidence Valuation 9.2/20 · P/E 26× · PEG n/a · 50% evidence Relative strength 2.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -11.7% · Strength vs NIFTY 500 (same reading) -9.5% · 1 year -23.5% · 100% evidence · 5 of 12 weeks ahead Exact sum: 8.3 + 15.4 + 9.2 + 2.5 = 35.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics](https://www.sectoralpha.in/sectors/diagnostics), all 9 compared on one page. ## Which companies are close to 3B Blackbio DX in size? 3B Blackbio DX is the 8th largest of 9 Diagnostics companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Metropolis Healthcare, Thyrocare Technologies, Vimta Labs, Krsnaa Diagnostics and Suraksha Diagnostic. Just below it: One Global Service Provider. ### Diagnostics companies close in size 1. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) ₹11,746 crore 2. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) ₹8,421 crore 3. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) ₹2,090 crore 4. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) ₹1,684 crore 5. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) ₹1,623 crore 6. 3B Blackbio DX Ltd ₹1,120 crore 7. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ₹729 crore [All 9 Diagnostics companies, largest first](https://www.sectoralpha.in/sectors/diagnostics#all-companies) ### Companies close in size in other industries 1. [String Metaverse Ltd](https://www.sectoralpha.in/stocks/string-metaverse-ltd) ₹1,120 crore · IT - Software 2. [N R Agarwal Industries Ltd](https://www.sectoralpha.in/stocks/n-r-agarwal-industries-ltd) ₹1,120 crore · Paper 3. 3B Blackbio DX Ltd ₹1,120 crore 4. [Macfos Ltd](https://www.sectoralpha.in/stocks/macfos-ltd) ₹1,119 crore · E-Commerce - Platform - Utility 5. [IZMO Ltd](https://www.sectoralpha.in/stocks/izmo-ltd) ₹1,114 crore · IT - Software ## What else do people ask about 3B Blackbio DX? ### What were 3B Blackbio DX's latest quarterly results? 3B Blackbio DX Ltd reported revenue of ₹48.0 Cr and net profit of ₹18.0 Cr for the Sep 2026 quarter. Revenue rose 41.2% and profit rose 20.0% compared with a year earlier. Earnings per share were ₹20.74. The operating margin was 43.8%, 0.3 percentage points lower than a year earlier (as of 20 November 2026). ### What is 3B Blackbio DX's market cap? 3B Blackbio DX Ltd's market capitalisation is ₹1,119 Cr at a share price of ₹1,305.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026). ### How is 3B Blackbio DX performing? 3B Blackbio DX Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 41.2% and profit rose 20.0% compared with a year earlier. This describes what the data did, not a rating (as of 20 November 2026). ### Will 3B Blackbio DX's share price go up? This page does not forecast 3B Blackbio DX Ltd's share price. What it shows instead: the share price is ₹1,305.10, and it has been rising for 7 weeks. Its P/E of 19.1× is higher than 56% of its own last 11 years (as of 20 November 2026). ### Who owns 3B Blackbio DX? Promoters own 41.0% of 3B Blackbio DX Ltd, foreign institutions 2.5%, domestic institutions 2.3% and the public 54.3% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026). ### Where is 3B Blackbio DX in its business cycle? 3B Blackbio DX Ltd's FY26 operating margin was 40.1%, against a 13-year range of 4.5% to 66.1%. The latest quarter was 43.8%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026). ### What could break the 3B Blackbio DX story? Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026). ### Is 3B Blackbio DX a stock worth studying right now? What the numbers show: 3B Blackbio DX Ltd's earnings have grown faster than its share price. Earnings per share grew +22.9% in a year while the price moved +1.8%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026). ## Lists - Healthcare & hospital stocks: https://www.sectoralpha.in/sectors/healthcare-stocks-india This is research, not advice. We’re not SEBI-registered.